TrialBlood2026

CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.

Steven Knapper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.